InterPAD - DETAILS

temozolomide, 85622-93-1, Methazolastone, Temodar, Temodal, 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, Temozolamide, Sch 52365, CCRG-81045, Temozolomidum [Latin], Temozolodida [Spanish], Temozolomidum, CCRG 81045, Sch-52365, NSC 362856, M&B 39831, M&B-39831, NSC-362856, CCRIS 8996, MB 39831, 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one, M & B 39831, BRN 5547136, M-39831, 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, NSC362856, CHEMBL810, 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide, MLS002701861, YF1K15M17Y, DTXSID5043714, CHEBI:72564, Mk-7365, 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, MFCD00866492, TMZ, NCGC00167429-01, Temozolodida, 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE, DTXCID3023714, C6H6N6O2, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide., 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide, SMR000466338, Temodal (TN), Temodar (TN), CAS-85622-93-1, Temozolomide, VETRANAL(TM), analytical standard, SR-01000759347, temozolomida, UNII-YF1K15M17Y, Temozolomide (JAN/USAN/INN), Temozolomide [USAN:INN:BAN], 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide, 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-, TEMOZOLIMIDE, Temozolomide- Bio-X, TEMOZOLOMIDE [MI], TEMOZOLOMIDE [INN], TEMOZOLOMIDE [JAN], Temodar (TN) (Schering), TEMOZOLOMIDE [USAN], SCHEMBL3739, 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, TEMOZOLOMIDE [VANDF], TEMOZOLOMIDE [MART.], MLS000759447, MLS001424028, BIDD:GT0204, TEMOZOLOMIDE [USP-RS], TEMOZOLOMIDE [WHO-DD], GTPL7301, TEMOZOLOMIDE [EMA EPAR], Temozolomide, >=98% (HPLC), GLXC-02560, HMS2051O12, HMS2090B08, HMS2232N13, HMS3264I14, HMS3269P05, HMS3372K13, HMS3393O12, HMS3413D06, HMS3654N05, HMS3677D06, HMS3713H16, Pharmakon1600-01502289, TEMOZOLOMIDE [ORANGE BOOK], TEMOZOLOMIDE [EP MONOGRAPH], 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, ALBB-021358, BCP03692, TEMOZOLOMIDE [USP MONOGRAPH], Tox21_112433, AC-758, BDBM50034562, DL-190, NSC759883, s1237, STK623541, 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide, AKOS005557098, Tox21_112433_1, CCG-100870, CS-0943, DB00853, KS-1216, NC00120, NSC-759883, Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, NCGC00167429-02, NCGC00167429-04, NCGC00167429-05, BP-25388, BT164447, HY-17364, NCI60_003316, BCP0726000154, Temozolomide 100 microg/mL in Acetonitrile, AM20110227, FT-0630936, FT-0674845, NS00004198, SW197500-4, T2744, D06067, EN300-122324, AB00639915-06, AB00639915-08, AB00639915-09, AB00639915_10, AB00639915_11, A841386, Q425088, Q-201786, SR-01000759347-4, SR-01000759347-5, BRD-K32107296-001-04-5, Z1201620684, 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide, Temozolomide, United States Pharmacopeia (USP) Reference Standard, 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-METHYL-4-OXO-8-IMIDAZOLO[5,1-D][1,2,3,5]TETRAZINECARBOXAMIDE, 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-, Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material, 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide), 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide)

No.	Title	Href
1	Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. Pathol Res Pract. 2023 May;245:154427. doi: 10.1016/j.prp.2023.154427.	`Click`
2	Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022 May;99:154016. doi: 10.1016/j.phymed.2022.154016.	`Click`
3	Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway. Environ Toxicol. 2023 Jan;38(1):90-100. doi: 10.1002/tox.23664.	`Click`
4	Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran J Basic Med Sci. 2016 Aug;19(8):890-898.	`Click`
5	Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells. Asian Pac J Cancer Prev. 2021 Dec 1;22(12):4001-4009. doi: 10.31557/APJCP.2021.22.12.4001.	`Click`
6	Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol (Dordr). 2017 Jun;40(3):247-261. doi: 10.1007/s13402-017-0320-1.	`Click`
7	Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. Int J Mol Sci. 2023 May 29;24(11):9453. doi: 10.3390/ijms24119453.	`Click`
8	Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52(2):377-391. doi:10.1016/j.freeradbiomed.2011.10.487	`Click`
9	Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications. Cancer Manag Res. 2020 Sep 11;12:8341-8354. doi: 10.2147/CMAR.S258584.	`Click`
10	Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther. 2012;18(7):536-546. doi:10.1111/j.1755-5949.2012.00319.x	`Click`
11	SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells. Molecules. 2019 Sep 5;24(18):3230. doi: 10.3390/molecules24183230.	`Click`
12	Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-κB Pathway. J Immunol Res. 2017;2017:9489383. doi: 10.1155/2017/9489383.	`Click`
13	Coumarins modulate the anti-glioma properties of temozolomide. Eur J Pharmacol. 2020 Aug 15;881:173207. doi: 10.1016/j.ejphar.2020.173207.	`Click`
14	Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines. Nutr Cancer. 2022;74(3):1071-1078. doi: 10.1080/01635581.2021.1952438.	`Click`
15	4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells. Sci Rep. 2023 Jun 8;13(1):9356. doi: 10.1038/s41598-023-35045-3.	`Click`
16	Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun;396(6):1247-1255. doi: 10.1007/s00210-023-02384-x.	`Click`
17	Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. Int J Mol Sci. 2023 Apr 10;24(8):6998. doi: 10.3390/ijms24086998.	`Click`
18	Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells. BMC Cancer. 2018 Apr 3;18(1):379. doi: 10.1186/s12885-018-4267-z.	`Click`
19	Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy. Comput Intell Neurosci. 2022 Jun 28;2022:5266770. doi: 10.1155/2022/5266770.	`Click`
20	Harmine Augments the Cytotoxic and Anti-invasive Potential of Temozolomide Against Glioblastoma Multiforme Cells. Jundishapur J Nat Pharm Prod. 2021. doi:10.5812/jjnpp.115464.	`Click`
21	Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. Invest New Drugs. 2019 Apr;37(2):223-237. doi: 10.1007/s10637-018-0620-y.	`Click`
22	Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells. Sci Rep. 2023 Dec 9;13(1):21835. doi: 10.1038/s41598-023-48777-z.	`Click`
23	Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC. J Cancer Res Clin Oncol. 2023 Nov;149(17):16055-16067. doi: 10.1007/s00432-023-05347-0.	`Click`
24	Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. Anticancer Res. 2019 Jan;39(1):57-66. doi: 10.21873/anticanres.13079.	`Click`
25	β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. Oncol Rep. 2015 Aug;34(2):943-51. doi: 10.3892/or.2015.4050.	`Click`
26	Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. Int J Mol Med. 2019 Mar;43(3):1478-1486. doi: 10.3892/ijmm.2019.4061.	`Click`
27	Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Int J Oncol. 2016 Feb;48(2):559-68. doi: 10.3892/ijo.2015.3271.	`Click`
28	Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel). 2021 Jul 6;13(14):3385. doi: 10.3390/cancers13143385.	`Click`
29	Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Cancer Lett. 2018 Aug 1;428:77-89. doi: 10.1016/j.canlet.2018.04.033.	`Click`
30	Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR. Molecules. 2023 Aug 11;28(16):6024. doi: 10.3390/molecules28166024	`Click`

No.

Title

Href

Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. Pathol Res Pract. 2023 May;245:154427. doi: 10.1016/j.prp.2023.154427.

Click

Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine. 2022 May;99:154016. doi: 10.1016/j.phymed.2022.154016.

Click

Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway. Environ Toxicol. 2023 Jan;38(1):90-100. doi: 10.1002/tox.23664.

Click

Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran J Basic Med Sci. 2016 Aug;19(8):890-898.

Click

Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells. Asian Pac J Cancer Prev. 2021 Dec 1;22(12):4001-4009. doi: 10.31557/APJCP.2021.22.12.4001.

Click

Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol (Dordr). 2017 Jun;40(3):247-261. doi: 10.1007/s13402-017-0320-1.

Click

Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. Int J Mol Sci. 2023 May 29;24(11):9453. doi: 10.3390/ijms24119453.

Click

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52(2):377-391. doi:10.1016/j.freeradbiomed.2011.10.487

Click

Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications. Cancer Manag Res. 2020 Sep 11;12:8341-8354. doi: 10.2147/CMAR.S258584.

Click

Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther. 2012;18(7):536-546. doi:10.1111/j.1755-5949.2012.00319.x

Click

SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells. Molecules. 2019 Sep 5;24(18):3230. doi: 10.3390/molecules24183230.

Click

Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-κB Pathway. J Immunol Res. 2017;2017:9489383. doi: 10.1155/2017/9489383.

Click

Coumarins modulate the anti-glioma properties of temozolomide. Eur J Pharmacol. 2020 Aug 15;881:173207. doi: 10.1016/j.ejphar.2020.173207.

Click

Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines. Nutr Cancer. 2022;74(3):1071-1078. doi: 10.1080/01635581.2021.1952438.

Click

4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells. Sci Rep. 2023 Jun 8;13(1):9356. doi: 10.1038/s41598-023-35045-3.

Click

Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun;396(6):1247-1255. doi: 10.1007/s00210-023-02384-x.

Click

Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. Int J Mol Sci. 2023 Apr 10;24(8):6998. doi: 10.3390/ijms24086998.

Click

Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells. BMC Cancer. 2018 Apr 3;18(1):379. doi: 10.1186/s12885-018-4267-z.

Click

Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy. Comput Intell Neurosci. 2022 Jun 28;2022:5266770. doi: 10.1155/2022/5266770.

Click

Harmine Augments the Cytotoxic and Anti-invasive Potential of Temozolomide Against Glioblastoma Multiforme Cells. Jundishapur J Nat Pharm Prod. 2021. doi:10.5812/jjnpp.115464.

Click

Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. Invest New Drugs. 2019 Apr;37(2):223-237. doi: 10.1007/s10637-018-0620-y.

Click

Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells. Sci Rep. 2023 Dec 9;13(1):21835. doi: 10.1038/s41598-023-48777-z.

Click

Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC. J Cancer Res Clin Oncol. 2023 Nov;149(17):16055-16067. doi: 10.1007/s00432-023-05347-0.

Click

Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. Anticancer Res. 2019 Jan;39(1):57-66. doi: 10.21873/anticanres.13079.

Click

β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. Oncol Rep. 2015 Aug;34(2):943-51. doi: 10.3892/or.2015.4050.

Click

Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. Int J Mol Med. 2019 Mar;43(3):1478-1486. doi: 10.3892/ijmm.2019.4061.

Click

Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Int J Oncol. 2016 Feb;48(2):559-68. doi: 10.3892/ijo.2015.3271.

Click

Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel). 2021 Jul 6;13(14):3385. doi: 10.3390/cancers13143385.

Click

Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Cancer Lett. 2018 Aug 1;428:77-89. doi: 10.1016/j.canlet.2018.04.033.

Click

Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR. Molecules. 2023 Aug 11;28(16):6024. doi: 10.3390/molecules28166024

Click

Name	Temozolomide
PubChem CID	5394
Molecular Weight	194.15g/mol
Synonyms	temozolomide, 85622-93-1, Methazolastone, Temodar, Temodal, 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, Temozolamide, Sch 52365, CCRG-81045, Temozolomidum [Latin], Temozolodida [Spanish], Temozolomidum, CCRG 81045, Sch-52365, NSC 362856, M&B 39831, M&B-39831, NSC-362856, CCRIS 8996, MB 39831, 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one, M & B 39831, BRN 5547136, M-39831, 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, NSC362856, CHEMBL810, 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide, MLS002701861, YF1K15M17Y, DTXSID5043714, CHEBI:72564, Mk-7365, 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, MFCD00866492, TMZ, NCGC00167429-01, Temozolodida, 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE, DTXCID3023714, C6H6N6O2, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide., 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide, SMR000466338, Temodal (TN), Temodar (TN), CAS-85622-93-1, Temozolomide, VETRANAL(TM), analytical standard, SR-01000759347, temozolomida, UNII-YF1K15M17Y, Temozolomide (JAN/USAN/INN), Temozolomide [USAN:INN:BAN], 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide, 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-, TEMOZOLIMIDE, Temozolomide- Bio-X, TEMOZOLOMIDE [MI], TEMOZOLOMIDE [INN], TEMOZOLOMIDE [JAN], Temodar (TN) (Schering), TEMOZOLOMIDE [USAN], SCHEMBL3739, 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide, TEMOZOLOMIDE [VANDF], TEMOZOLOMIDE [MART.], MLS000759447, MLS001424028, BIDD:GT0204, TEMOZOLOMIDE [USP-RS], TEMOZOLOMIDE [WHO-DD], GTPL7301, TEMOZOLOMIDE [EMA EPAR], Temozolomide, >=98% (HPLC), GLXC-02560, HMS2051O12, HMS2090B08, HMS2232N13, HMS3264I14, HMS3269P05, HMS3372K13, HMS3393O12, HMS3413D06, HMS3654N05, HMS3677D06, HMS3713H16, Pharmakon1600-01502289, TEMOZOLOMIDE [ORANGE BOOK], TEMOZOLOMIDE [EP MONOGRAPH], 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, ALBB-021358, BCP03692, TEMOZOLOMIDE [USP MONOGRAPH], Tox21_112433, AC-758, BDBM50034562, DL-190, NSC759883, s1237, STK623541, 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide, AKOS005557098, Tox21_112433_1, CCG-100870, CS-0943, DB00853, KS-1216, NC00120, NSC-759883, Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, NCGC00167429-02, NCGC00167429-04, NCGC00167429-05, BP-25388, BT164447, HY-17364, NCI60_003316, BCP0726000154, Temozolomide 100 microg/mL in Acetonitrile, AM20110227, FT-0630936, FT-0674845, NS00004198, SW197500-4, T2744, D06067, EN300-122324, AB00639915-06, AB00639915-08, AB00639915-09, AB00639915_10, AB00639915_11, A841386, Q425088, Q-201786, SR-01000759347-4, SR-01000759347-5, BRD-K32107296-001-04-5, Z1201620684, 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide, Temozolomide, United States Pharmacopeia (USP) Reference Standard, 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 3-METHYL-4-OXO-8-IMIDAZOLO[5,1-D][1,2,3,5]TETRAZINECARBOXAMIDE, 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-, {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-, Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material, 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide), 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide)
Drug Type	Small molecule
Formula	C₆H₆N₆O₂
SMILES	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
InChI	1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
InChIKey	BPEGJWRSRHCHSN-UHFFFAOYSA-N
CAS Number	85622-93-1
ChEMBL ID	CHEMBL810
ChEBI ID	CHEBI:72564
TTD ID	D0C8EU
Drug Bank ID	DB00853
KEGG ID	D06067
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Tubeimoside I, Temozolomide
Partner Name	Tubeimoside I
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	EGFR	hsa1956
	Down-regulation	Expression	MGMT	hsa4255
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	NFKB1	hsa4790
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
	Down-regulation	Phosphorylation	RELA	hsa5970
	Down-regulation	Phosphorylation	RHOBTB2	hsa23221
In Vitro Model	U-118MG	Astrocytoma	Homo sapiens (Human)	CVCL_0633
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
Result	We first demonstrated that synergistic effects of TBMS1 and TMZ induced apoptosis in GBM cells through reducing MGMT expression and inhibiting the EGFR induced PI3K/Akt/mTOR/NF-κB signaling pathway. This study provides a rationale for combined application of TMZ and TBMS1 as a potential chemotherapeutic treatment for MGMT+ GBM patients.

Pair Name	Thymoquinone, Temozolomide
Partner Name	Thymoquinone
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Phosphorylation	MAPK14	hsa1432
	Up-regulation	Expression	MGMT	hsa4255
In Vitro Model	M059J	Glioblastoma	Homo sapiens (Human)	CVCL_0400
	Hs 683	Oligodendroglioma	Homo sapiens (Human)	CVCL_0844
	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
In Vivo Model	U251R cells were prepared in a matrix mixture (50% wt/wt Matrigel in DMEM) and xenografted to each mouse (1×10⁶ cells in 0.5 ml) under the back skin.
Result	Our findings demonstrate that TQ can effectively cross the BBB and function alone or in combination with TMZ to treat glioblastoma.

Pair Name	Thymoquinone, Temozolomide
Partner Name	Thymoquinone
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Autophagy
Gene Regulation	Down-regulation	Expression	BECN1	hsa8678
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	TQ enhanced the anti-cancer activity of TMZ by inhibition of autophagy at the transcriptional level and decreased the colony-forming ability and NO production of U87MG cell line.

Pair Name	Taurine, Temozolomide
Partner Name	Taurine
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
In Vitro Model	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
Result	The study showed that the combination between TMZ and TAU has a potential in anticancer properties against U-251 MG manifested by the induction of G2/M arrest and apoptosis. These results suggest that this combination may be useful to enhance the efficacy and reduce some adverse events of GBM treatment in the future.

Pair Name	Shikonin, Temozolomide
Partner Name	Shikonin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Epithelial-mesenchymal transition
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	SNAI2	hsa6591
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	U-118MG	Astrocytoma	Homo sapiens (Human)	CVCL_0633
Result	From our results we conclude that dual treatment with SHK and TMZ may constitute a powerful new tool for GBM treatment by reducing therapy resistance and tumor recurrence.

Pair Name	Resveratrol, Temozolomide
Partner Name	Resveratrol
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	MGMT	hsa4255
	Up-regulation	Expression	PIAS3	hsa10401
	Up-regulation	Expression	PTPN11	hsa5781
	Up-regulation	Expression	PTPN6	hsa5777
	Up-regulation	Expression	SOCS3	hsa9021
	Down-regulation	Expression	STAT3	hsa6774
In Vitro Model	A-172	Glioblastoma	Homo sapiens (Human)	CVCL_0131
In Vitro Model	LN-428	Glioblastoma	Homo sapiens (Human)	CVCL_3959
Result	Res inhibited STAT3 signaling through modulation of PIAS3, SHP1, SHP2, and SOCS3, thereby attenuating tumor growth and increasing sensitivity to TMZ. Therefore, Res is an ideal candidate to be used in TMZ combined chemotherapy for GBM.

Pair Name	Pulsatilla saponin D, Temozolomide
Partner Name	Pulsatilla saponin D
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Triggering caspase-independent cell death
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Expression	CTSB	hsa1508
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Up-regulation	Expression	ROS1	hsa6098
	Up-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	SB365 inhibits autophagic flux and induces caspase-independent cell death in GBM cells in a manner involving cathepsin B and mainly reactive oxygen species, and its use in combination with temozolomide shows promise for the treatment of GBM.

Pair Name	Propyl gallate, Temozolomide
Partner Name	Propyl gallate
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->ROS generation
Gene Regulation	Down-regulation	Phosphorylation	CHUK	hsa1147
	Down-regulation	Phosphorylation	IKBKE	hsa9641
	Down-regulation	Activity	MMP2	hsa4313
	Down-regulation	Activity	MMP9	hsa4318
	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF- κ B Pathway

Pair Name	Osthol, Temozolomide
Partner Name	Osthol
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BECN1	hsa8678
	Up-regulation	Expression	CASP3	hsa836
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
In Vitro Model	MOG-G-CCM	Anaplastic astrocytoma	Homo sapiens (Human)	CVCL_2613
Result	Our results indicated that osthole effectively eliminated glioma cells via apoptosis, what was correlated with Bcl-2/Beclin 1 complex formation. Considering the anti-migratory effect, osthole and Temozolomide display antiglioma potential but it needs further extensive studies.

Pair Name	Naringenin, Temozolomide
Partner Name	Naringenin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Cell migration
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
In Vitro Model	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
Result	The study showed a marked reduction in the migration of the cells and the formation of a single cell colony.

Pair Name	Methoxsalen, Temozolomide
Partner Name	Methoxsalen
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Cell proliferation
Gene Regulation	Down-regulation	Expression	MMP2	hsa4313
In Vitro Model	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
In Vitro Model	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
Result	We showed a marked antitumor effect of 4MU on GBM cells alone and in combination with chemotherapy and proved, for the first time, the effect of 4MU on TMZ-resistant models, demonstrating that 4MU would be a potential therapeutic alternative for improving GBM therapy even on TMZ-refractory patients.

Pair Name	Lycorine, Temozolomide
Partner Name	Lycorine
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->ROS generation
Gene Regulation	Up-regulation	Expression	IKBKE	hsa9641
Gene Regulation	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	C6	Rat malignant glioma	Rattus norvegicus (Rat)	CVCL_0194
Result	Our study suggested that lycorine exerts an anti-glioma effect by inducing ROS production and inhibiting NF-κB, which validated that lycorine may be a potential candidate for glioma treatment alone or in combination with TMZ.

Pair Name	Juglone, Temozolomide
Partner Name	Juglone
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Expression	OGG1	hsa4968
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
	U-138MG	Astrocytoma	Homo sapiens (Human)	CVCL_0020
	U-118MG	Astrocytoma	Homo sapiens (Human)	CVCL_0633
Result	Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line

Pair Name	Honokiol, Temozolomide
Partner Name	Honokiol
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis and autophagy
Gene Regulation	Up-regulation	Expression	CASP3	hsa836
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
In Vitro Model	GL261	Glioblastoma	Mus musculus (Mouse)	CVCL_Y003
Result	Taken together, this study demonstrated the improved effects of honokiol with TMZ on autophagy and subsequent apoptosis of drug-sensitive and -tolerant glioma cells. Thus, honokiol has the potential to be a drug candidate for treating human gliomas.

Pair Name	Hispidulin, Temozolomide
Partner Name	Hispidulin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Autophagy
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Expression	MAP1LC3B	hsa81631
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	These results collectively suggested that the combination of hispidulin and TMZ could improve the antitumor efficiency of TMZ against malignant gliomas.

Pair Name	Harmine, Temozolomide
Partner Name	Harmine
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Gene Regulation	Down-regulation	Expression	MMP2	hsa4313
Gene Regulation	Down-regulation	Expression	MMP9	hsa4318
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
Result	Harmine Augments the Cytotoxic and Anti-invasive Potential of Temozolomide Against Glioblastoma Multiforme Cells

Pair Name	Euphol, Temozolomide
Partner Name	Euphol
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Up-regulation	Expression	MAP1LC3B	hsa81631
In Vitro Model	GaMG	Glioblastoma	Homo sapiens (Human)	CVCL_1226
In Vitro Model	U-373MG ATCC	Astrocytoma	Homo sapiens (Human)	CVCL_2219
Result	These findings provide experimental support for further development of euphol as a novel therapeutic agent for GBM, either alone or in combination chemotherapy.

Pair Name	Cryptotanshinone, Temozolomide
Partner Name	Cryptotanshinone
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Gene Regulation	Up-regulation	Expression	H2AX	hsa3014
	Down-regulation	Expression	MGMT	hsa4255
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	Combined treatment with CTS and TMZ might be an effective option to overcome the chemoresistance of GBM cells in a long-term treatment strategy.

Pair Name	Cordycepin, Temozolomide
Partner Name	Cordycepin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Inhibition-->Cell metastasis
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Down-regulation	Expression	CTNNB1	hsa1499
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	NFKB1	hsa4790
	Up-regulation	Expression	PDCD4	hsa27250
	Down-regulation	Expression	TWIST1	hsa7291
	Down-regulation	Expression	ZEB1	hsa6935
In Vitro Model	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
Result	Cordycepin combined with temozolomide may down-regulate MYC through "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway", which in turn regulate the expression of MCL1, CTNNB1, MMP9, PDCD4, thus regulating cell proliferation, migration and apoptosis in glioblastoma.

Pair Name	Biochanin A, Temozolomide
Partner Name	Biochanin A
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Glycolytic to oxidative phosphorylation
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Expression	EGFR	hsa1956
	Down-regulation	Phosphorylation	MAPK3	hsa5595
	Down-regulation	Expression	MYC	hsa4609
	Up-regulation	Phosphorylation	TP53	hsa7157
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
Result	Chanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells.

Pair Name	Beta-Elemene, Temozolomide
Partner Name	Beta-Elemene
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Phosphorylation	ATM	hsa472
	Down-regulation	Expression	H2AX	hsa3014
	Down-regulation	Expression	MAPK3	hsa5595
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
	LN-229	Glioblastoma	Homo sapiens (Human)	CVCL_0393
	C6	Rat malignant glioma	Rattus norvegicus (Rat)	CVCL_0194
Result	These results revealed that β-elemene could significantly increase the radiosensitivity and chemosensitivity of GBM. β-elemene may be used as a potential drug in combination with the radiotherapy and chemotherapy of GBM

Pair Name	Acteoside, Temozolomide
Partner Name	Acteoside
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis and autophagy
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Phosphorylation	MAPK1	hsa5594
	Up-regulation	Phosphorylation	MAPK14	hsa1432
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Up-regulation	Expression	RAB7A	hsa7879
	Up-regulation	Expression	SQSTM1	hsa8878
	Up-regulation	Phosphorylation	TP53	hsa7157
In Vitro Model	C6	Rat malignant glioma	Rattus norvegicus (Rat)	CVCL_0194
Result	It was also determined that TMZ + acteoside induced apoptosis and autophagy through the mitogen‑activated protein kinase signaling pathway. These findings suggest that acteoside has beneficial effects on TMZ‑based glioblastoma therapy.

Pair Name	Sulforaphane, Temozolomide
Partner Name	Sulforaphane
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	CASP3	hsa836
	Down-regulation	Expression	MGMT	hsa4255
	Down-regulation	Expression	MKI67	hsa4288
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	RELA	hsa5970
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
In Vitro Model	U-373MG ATCC	Astrocytoma	Homo sapiens (Human)	CVCL_2219
In Vivo Model	Nude mouse models were established with U373-R GBM cells inoculated subcutaneously into the right flanks of 4–6-week-old female mice.
Result	The present study suggests that the clinical efficacy of TMZ-based chemotherapy in TMZ-resistant GBM may be improved by combination with SFN.

Pair Name	Perillyl alcohol, Temozolomide
Partner Name	Perillyl alcohol
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
	U-937	Adult acute monocytic leukemia	Homo sapiens (Human)	CVCL_0007
In Vivo Model	For U937 cell implantation, used NSG-SGM3 mice and intravenously (via tail vein) injected 5×10⁴ tumor cells in a volume of 200 µL 0.9% NaCl. For 4D9 and 6D10 cells, used NOD-SCID mice.
Result	Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia

Pair Name	Parthenolide, Temozolomide
Partner Name	Parthenolide
Disease Info	[ICD-11: 2F7Z]	Glioma		Investigative
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	MGMT	hsa4255
	Down-regulation	Activity	NFKB1	hsa4790
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	T98G	Glioblastoma	Homo sapiens (Human)	CVCL_0556
In Vitro Model	LN-18	Glioblastoma	Homo sapiens (Human)	CVCL_0392
Result	These findings suggest that NF-κB is a potential target for inducing cell death in gliomas. A targeted combination strategy in which the response to TMZ is synergistically enhanced by the addition of parthenolide which may be useful, especially in chemoresistant gliomas with high MGMT expression.

Pair Name	Aloe emodin, Temozolomide
Partner Name	Aloe emodin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	MGMT	hsa4255
Gene Regulation	Down-regulation	Expression	NFKB1	hsa4790
In Vitro Model	IRCC-Neuromed-NULU	Glioblastoma	Homo sapiens (Human)	CVCL_B1D1
In Vitro Model	IRCC-Neuromed-ZAR	Glioblastoma	Homo sapiens (Human)	CVCL_B1CY
Result	These convincing results suggest that AE could be a natural adjuvant agent to potentiate the effects of traditional drugs (TMZ) and overcome drug resistance in glioblastoma cells.

Pair Name	Curcumin, Temozolomide
Partner Name	Curcumin
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BDNF	hsa627
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	HSP90AA1	hsa3320
	Down-regulation	Expression	HSPA4	hsa3308
	Down-regulation	Expression	HSPB1	hsa3315
	Up-regulation	Expression	TNF	hsa7124
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
Result	We showed for the first time that exosomes released from drug-treated U87 cells could be a new therapeutic approach in glioblastoma, and could reduce the side effects produced by drugs alone. This concept needs to be further examined in animal models before clinical trials could be considered.